Evgen Pharma PLC
LSE:EVG

Watchlist Manager
Evgen Pharma PLC Logo
Evgen Pharma PLC
LSE:EVG
Watchlist
Price: 0.8 GBX Market Closed
Market Cap: £3.4m

Operating Margin

-518%
Current
Improving
by 318.4%
vs 3-y average of -836.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-518%
=
Operating Income
£-4.3m
/
Revenue
£838k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-518%
=
Operating Income
GBX-4.3m
/
Revenue
£838k

Peer Comparison

Country Company Market Cap Operating
Margin
UK
Evgen Pharma PLC
LSE:EVG
3.4m GBP
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 99% of companies in United Kingdom
Percentile
1st
Based on 3 579 companies
1st percentile
-518%
Low
-195 650% — 0%
Typical Range
0% — 0.2%
High
0.2% — 4 630.7%
Distribution Statistics
United Kingdom
Min -195 650%
30th Percentile 0%
Median 0.1%
70th Percentile 0.2%
Max 4 630.7%

Evgen Pharma PLC
Glance View

Market Cap
3.4m GBX
Industry
Biotechnology

Evgen Pharma Plc is a clinical stage drug development company, which engages in the development of pharmaceutical products and focus on cancer and neurological disease. The company is headquartered in Wilmslow, Cheshire and currently employs 8 full-time employees. The company went IPO on 2015-10-21. The firm is developing sulforaphane-based medicines focused on the treatment of cancer and inflammation. The firm's pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01 for the treatment of metastatic breast cancer and acute respiratory distress syndrome. The SFX-01 reduces the number of cancer stem cells in patient-derived breast cancer tissue in xenograft models. Its SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin.

EVG Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-518%
=
Operating Income
£-4.3m
/
Revenue
£838k
What is Evgen Pharma PLC's current Operating Margin?

The current Operating Margin for Evgen Pharma PLC is -518%, which is above its 3-year median of -836.4%.

How has Operating Margin changed over time?

Over the last 3 years, Evgen Pharma PLC’s Operating Margin has increased from -1 757.2% to -518%. During this period, it reached a low of -1 757.2% on Sep 30, 2020 and a high of -518% on Oct 30, 2023.

Back to Top